What question did this study set out to answer?

January 1, 1974CancerOpen Access

Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule

View Full Paper

Ask AI

Bookmark

Why the study?

Does an intermittent single high-dosage schedule of adriamycin provide efficacy and safety in patients with malignancies?

Population

96 patients with malignancies

Design

Case_series

Authors

RBRobert S. BenjaminCardio-Oncology PWPeter H. WiernikMount Sinai Hospital NBNicholas R. BachurUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Discussion

Member takes

Implication

Supports exploration of intermittent high-dose adriamycin; leaves open its role pending controlled trials.

Key Points

To assess the efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule of adriamycin in cancer treatment.
Evaluated 96 patients treated with a dosage of 60 mg/m2 I.V. q 3 weeks.
Conducted pharmacokinetic studies to analyze plasma levels and urinary excretion of adriamycin.
Monitored patient outcomes, including remissions in various malignancies and dose adjustments for liver function.
10 out of 25 patients with sarcomas achieved complete or partial remission.
9 out of 31 patients with carcinomas had similar outcomes.
22 out of 48 patients showed improvement, highlighting the effectiveness of the treatment.

Structured PICO

Does an intermittent single high-dosage schedule of adriamycin provide efficacy and safety in patients with malignancies?

Population

96 patients with malignancies (82 evaluable: 25 with sarcomas, 31 with carcinomas, and 26 with hematologic malignancies)

Intervention

Adriamycin 60 mg/m2 I.V. every 3 weeks

Outcome

Complete or partial remission and pharmacokinetic/safety profile

An intermittent single high-dosage schedule of adriamycin (60 mg/m2 I.V. every 3 weeks) is efficacious across various malignancies, but requires a 50-75% dose reduction in patients with impaired liver function to avoid severe toxicity.

Cite This Study

Benjamin et al. (1974) studied this question.

synapsesocial.com/papers/69f7e2ea6d1e8212df5a2c0c https://doi.org/10.1002/1097-0142(197401)33:1<19::aid-cncr2820330107>3.0.co;2-m

View Full Paper

Ask AI

Bookmark

Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider